Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
68 hedge funds and large institutions have $125M invested in Viracta Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 19 increasing their positions, 15 reducing their positions, and 8 closing their positions.
75% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 8
27% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 15
8% more funds holding
Funds holding: 63 → 68 (+5)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
18% less capital invested
Capital invested by funds: $152M → $125M (-$27.3M)
26% less call options, than puts
Call options by funds: $497K | Put options by funds: $673K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$10.5M |
| 2 |
ASP
Adams Street Partners
Chicago,
Illinois
|
+$7.19M |
| 3 |
JP Morgan Chase
New York
|
+$5.56M |
| 4 |
Blackstone Inc
New York
|
+$2.35M |
| 5 |
State Street
Boston,
Massachusetts
|
+$920K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$4.49M |
| 2 |
KHCM
Kettle Hill Capital Management
New York
|
-$2.1M |
| 3 |
B
Bailard
Foster City,
California
|
-$936K |
| 4 |
Goldman Sachs
New York
|
-$890K |
| 5 |
Janus Henderson Group
London,
|
-$630K |
VIRX Hedge Fund Activity: Q3 2021 in Review
68 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2021, worth a combined $125M — down 18% from $152M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new VIRX positions and 8 closed out — a net gain of 6 holders — while 19 added to existing stakes and 15 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $10.5M. The largest seller was Sectoral Asset Management, exiting entirely with an estimated $4.49M sold.
- 68 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2021, up from 63 in Q2 2021.
- Funds reported $125M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2021, down 18% quarter-over-quarter.
- 14 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2021 and 8 closed out, a net change of +6 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2021 was T. Rowe Price Associates, an estimated $10.5M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2021 was Sectoral Asset Management, an estimated $4.49M sold.
Based on aggregated 13F filings for Q3 2021.